Miami-based Rho Nutrition, a fast-growing maker of liquid vitamins, is exploring a sale that could value the company at more than $500 million, according to people familiar with the matter. The privately held brand, co-founded in 2022 by supplement industry veterans Ryan Bishop and George Padilla, is working with investment bank Rothschild on an early-stage sale process.
Rho expects to generate about $200 million in revenue this year, driven by its line of liposome-based liquid vitamins. These products use tiny fat-like bubbles to encase nutrients, which the company says helps protect them during digestion and improves absorption compared with traditional pills.
The potential deal comes as the broader vitamins and supplements sector sees a surge in merger activity. Big consumer goods companies are looking for growth in wellness, and they are increasingly willing to pay premium prices for brands with strong consumer appeal.
Why supplements are suddenly hot
Demand for vitamins and supplements has been climbing as more shoppers prioritize health and wellness. But a newer factor is also at play: the rise of GLP-1 weight-loss drugs. Some users of these medications turn to supplements to help offset side effects such as muscle loss, creating a fresh wave of demand for products like protein powders, electrolytes, and specialized vitamins.
That combination has kept dealmaking active. Recent transactions include Procter & Gamble's agreement to buy vitamin brand Thorne for $3.8 billion, Unilever's purchase of gummy brand Grüns, and private equity firm Yellow Wood Partners' deal to acquire Nestlé's mainstream vitamins business. These moves show that both strategic buyers and financial investors see long-term potential in the category.
Rho Nutrition and Rothschild declined to comment on the reported sale process.
What a $500 million price tag means
If Rho lands a valuation above $500 million, that would work out to roughly 2.5 times its expected $200 million in sales for this year. In consumer health, the price-to-sales ratio is a common shortcut for valuing companies when profit margins aren't disclosed. Buyers often justify paying such multiples if they believe their distribution networks and marketing muscle can put the same brand on more shelves and websites, boosting sales without a proportional rise in costs.
For investors, Rho's potential sale is more than a single deal. It becomes a reference point for pricing other vitamins, minerals, and supplements targets. It also signals how much large consumer companies like Procter & Gamble and Unilever may be willing to pay for growth in the category.
What it means for everyday investors
For most people, Rho Nutrition is not a stock they can buy directly—it's privately held. But the deal matters for investors in public companies that compete in the wellness space, as well as for those who own shares in the big consumer giants doing the acquiring.
When a private brand fetches a high multiple, it can lift the perceived value of similar public companies. It can also signal that large players are confident enough in the long-term demand for supplements to pay up, which may be a positive sign for the entire sector.
At the same time, the flurry of deals highlights a broader trend: consumer companies are increasingly looking to bolt-on acquisitions to drive growth, rather than relying solely on their existing brands. That strategy can be good for shareholders if the acquired brands perform well, but it also carries integration risks.
For now, the Rho sale is still in its early stages, and there's no guarantee a deal will happen. But the fact that a two-year-old brand can command a nine-figure valuation speaks to the strength of the current supplement boom—and to how much big consumer companies are willing to pay to get a piece of it.
